ArticleJournal of medical biochemistry2025
The role of GH/IGF-1 axis dysfunction and inflammatory cytokines in pediatric short stature.
Article in Journal of medical biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Short stature in children is a common clinical condition frequently associated with abnormalities in the GH/IGF-1 axis. Emerging evidence points to the involvement of inflammatory cytokines and serum markers in modulating this dysfunction. This study aims to investigate the molecular pathways underlying GH/IGF-1 axis impairment and assess the levels of inflammatory cytokines and other related biomarkers in children with short stature. Methods: A total of 150 children diagnosed with short stature were recruited from the endocrinology department of a tertiary care hospital. An ageand sex-matched group of 150 healthy children served as controls for comparison. Serum concentrations of growth hormone (GH), insulin-like growth factor-1 (IGF-1), interleukin-6 (IL-6), interleukin-8 (IL-8), and other relevant biomarkers were measured using enzyme-linked immunosorbent assay (ELISA). Genetic testing was performed to detect mutations in genes involved in the GH/IGF-1 signalling pathway. Data analysis was conducted using SPSS software, with statistical significance set at p< 0.05. Results: Children with short stature showed significantly reduced GH and IGF-1 levels (p< 0.001) and elevated IL-6 and IL-8 levels (p< 0.01). A moderate negative correlation was found between IL-6 and IGF-1 levels (r=-0.45, p< 0.001), suggesting that inflammation may impair growth signalling. GHR gene mutations were significantly more common in the short stature group (14.7% vs. 2.7%, p< 0.001) and were associated with lower IGF-1 levels. Conclusions: This findings of the study suggest that impaired GH/IGF-1 signalling, increased inflammatory cytokines, and a higher prevalence of GHR gene mutations collectively contribute to the pathophysiology of pediatric short stature. These results highlight the need for integrative diagnostic approaches and future therapeutic strategies that target both endocrine and inflammatory pathways.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.